Setmelanotide
Fat LossFDA-approved MC4R agonistEstablished
FDA-approved MC4R agonist (Imcivree) for rare genetic obesities (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). Daily SC injection, not a general-obesity drug.
For research use only.
Key Facts
- CAS
- 920014-72-8
- Molecular Weight (MW)
- 1117.3 g/mol
- Half-life
- ~11 hours
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- 8/23/2026
- Targets
- MC4R
Overview
FDA-approved MC4R agonist (Imcivree) for rare genetic obesities (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). Daily SC injection, not a general-obesity drug.
Protocol
- Dosage Range
- Titrated from 1 mg to 2-3 mg daily based on response
- Frequency
- Once daily
- Cycle
- Long-term use as prescribed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Reconstitute with sterile water for injection per package insert
Science
Mechanism of Action
MC4R agonist that restores anorexigenic signaling downstream of leptin in specific monogenic/syndromic obesities.
Targets
MC4R
Studies
- Setmelanotide in POMC deficiency— Journal/year not available
Benefits
Labeled rare genetic obesity therapy
Potential Side Effects
- Hyperpigmentation
- Nausea
- Sexual-arousal disturbances
- Injection reactions
References
- FDA label — ImcivreeExternal link · Year —